Publications by authors named "S Cheong"

High-energy nuclear collisions create a quark-gluon plasma, whose initial condition and subsequent expansion vary from event to event, impacting the distribution of the eventwise average transverse momentum [P([p_{T}])]. Disentangling the contributions from fluctuations in the nuclear overlap size (geometrical component) and other sources at a fixed size (intrinsic component) remains a challenge. This problem is addressed by measuring the mean, variance, and skewness of P([p_{T}]) in ^{208}Pb+^{208}Pb and ^{129}Xe+^{129}Xe collisions at sqrt[s_{NN}]=5.

View Article and Find Full Text PDF

Conventionally, megakaryocytes (MKs) are regarded as platelet-producing cells and their platelet-related functions in haemostasis have been well documented. However, it is increasingly evident that MKs have functions beyond platelet production. Convincing findings suggest that MKs are active participants in immunity and infections.

View Article and Find Full Text PDF

Ethnopharmacological Relevance: The pharmacological potential of marine organisms remains largely unexplored. commonly known as Pae, is extensively distributed over Asia. Its antioxidant, antibacterial, antiobesity, and anti-inflammatory properties are also being investigated.

View Article and Find Full Text PDF

Small interfering RNAs (siRNA) technology has emerged as a promising therapeutic tool for human health conditions like cancer due to its ability to regulate gene silencing. Despite FDA-approved, their delivery remains localized and limiting their systemic use. This study used single-walled carbon nanotubes (SWNTs) functionalized with polyethylene glycolated (PEGylated) phospholipids (PL-PEG) derivatives for systemic siRNA delivery.

View Article and Find Full Text PDF
Article Synopsis
  • The study aims to evaluate the effectiveness of combining pembrolizumab with platinum and gemcitabine (PG) as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in Malaysia, comparing it to the existing treatment with pembrolizumab plus platinum and 5-fluorouracil (PF).
  • It is a phase 2, open-label, multicenter study enrolling up to 89 participants, where pembrolizumab will be administered alongside chemotherapy for six cycles, and various response and safety metrics will be assessed.
  • The trial has received ethical approval and its results will be shared through conferences and scientific publications, aiming to contribute valuable findings to cancer treatment discussions.
View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: A non-numeric value encountered

Filename: controllers/Author.php

Line Number: 219

Backtrace:

File: /var/www/html/application/controllers/Author.php
Line: 219
Function: _error_handler

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: A non-numeric value encountered

Filename: libraries/Pagination.php

Line Number: 413

Backtrace:

File: /var/www/html/application/controllers/Author.php
Line: 274
Function: create_links

File: /var/www/html/index.php
Line: 316
Function: require_once